About us
EQL Pharma is an entrepreneurial pharmaceutical company focusing on simplicity and efficiency at all levels of the value chain in order to be able to deliver cost-efficient medicines of highest quality to pharmacies and hospitals, primarily in the Nordic region.
The company conducts extensive development activities in collaboration with partners in Asia, Europe and India. Our strategy is to develop generic medicines in areas where the competition is limited, so-called niche generics. We do not focus on specific therapeutic areas, but rather on the opportunities we can identify in the Nordic market for prescription medicines sold in pharmacies or used in hospitals.
Our entire business is based on us delivering the cheapest medicines to pharmacies and hospitals, in this way daily lowering the cost of high-quality drugs for patients and society.
Business Strategy
EQL Pharma focuses on niche generics, i.e. pharmaceuticals that have little or no competition despite lacking patent protection. The reason for the limited competition is that these drugs often have a small turnover globally, but a relatively larger turnover in a specific geography, such as a country or a region of countries. The larger international companies do not consider these drugs to be of interest in developing because the total continental or global turnover is too small.
EQL Pharma is specializing on generic medicines that have little or no competition in the Nordic region. The reason for the limited competition is often that these medicines have a small sale globally, but a relatively larger turnover in the Nordic countries. The major international generic companies have so far not considered that these local drugs are of interest since the total turnover has been too small.
As niche generics are not normally available for purchase, or license, as fully developed products, the company conducts extensive development work on these in close collaboration with partners in Europe, India and China. The entry barrier for potential competitors is therefore significantly higher for these niche generics than for regular generics, as these niche products are EQL Pharma’s own products. No other player has the opportunity to sell them without developing them themselves.
Vision, Mission and Values
Be a driving force for medical accessibility by offering tested therapies to new European markets and thereby contribute to equal and optional care.
Reduce healthcare costs in Europe by identifying, developing and offering top-quality niche generics for the benefit of both patients and society.
We follow routines and guidelines, but are not afraid to find new ways to solve tasks, or adapt to changing market needs.
We never give up, but continue until a solution is in place. It is important to create results, set new goals and achieve them. We wish to constantly improve ourselves.
We achieve good results with limited resources, we strive for simplicity and clarity.
We stand behind our products and decisions and take full responsibility for that our affordable new medicines offer the quality and customer value that the market expects.
We cannot do it alone. We listen and learn from each other, regardless of location or function and adapt in order to take advantage of our collective resources and insights.
We are passionate in our commitment, and challenge status quo in order to find new and better solutions for our patients and customers.
Our aim is to achieve the highest possible standards in our processes, products and services, and provide a safe and rewarding work environment for our employees.
Management

Axel Schörling
President and CEO
Education
MSc Engineering Physics, Chalmers and MSc Financial Economics, School of Business in Gothenburg.
Born
1986
Holding
257113 shares and 400000 call options
Work experience
Axel Schörling has a background as a management consultant at BearingPoint and most recently came from a role as Director of Perstorp’s Business Controlling team. Overall, he has extensive experience from a number of industries and assignments in logistics and supply chain from an operational / financial perspective.

Martin Kristofferson
COO
Education
MSc Business Administration, Linköping University
Born
1978
Holding
15200 shares and 46000 call options
Work experience
Martin Kristofferson has held numerous Sourcing and Procurement positions in the life science industry, most recently as responsible for CMO and Medical Devices Procurement at Leo Pharma in Copenhagen. Martin has also lived and worked in India as part of the AstraZeneca Global Branded Generics initiative.

Anna Jönsson
CFO
Education
Degree from IHM Business School in economics and accounting
Born
1984
Holding
13 729
Work experience
Anna has more than ten years of experience from the accounting and auditing industry. She has worked as a qualified accounting consultant and office manager in Lund at Resursgruppen Ekonomi & Revision AB. Anna has previously been CFO for the listed companies Amniotics AB and Respiratorius AB.

Alexander Brising
Business Development Director
Education
MSc Business Administration, Management & Operations from the Gothenburg School of Economics
Born
1970
Holding
356 543
Work experience
Alexander Brising has held a number of marketing and business development assignments in the pharmaceutical industry, most recently coming from Sandoz Nordic Headquarters in Copenhagen and an assignment as Commercial Head Sweden.

Cornelia Lindström
Reg/QA/PV Director
Education
MSc Pharm, Leg. Pharmacist, Uppsala University
Born
1986
Holding
46000 call options
Work experience
Cornelia has extensive experience of Regulatory Affairs and Quality Assurance in various positions in the pharmaceutical industry and most recently came from a role as Head of Regulatory Affairs and Pharmacovigilance at Bayer Animal Health in Copenhagen.

Carl Lindgren
Chief Business Development Officer
Education
B.Sc., Business Administration and Economics, Lund University
Born
1968
Holding
None
Work experience
Carl Lindgren has more than 25 years of experience from the Life Science industry within multinational companies like AstraZeneca PLC, Lundbeck A/S and Karo Pharma AB. He most recently joined from a position as VP M&A/Business Development within the executive management team of Karo Healthcare AB. Carl is furthermore Member of the Board of Iconovo AB and Biomedica Norden AB.
Board of Directors

Christer Fåhraeus
Chairman of the Board
Education
BA, MSc Biotechnology, PhD hc
Born
1965
Holding
9 310 271 via companies
Independent
No
Assumed
Board member since 2006
Professional experience
Chairman of FlatFrog Laboratories AB, Respiratorius AB (plc) and Longboat Explorers AB. Member of the board of CellaVision AB (plc), LU Innovation AB and Reccan AB. Former CEO of CellaVision AB (plc), Anoto Group AB (plc), Flatfrog Laboratories and Agellis Group AB (plc).

Anders Månsson
Board member
Education
BSc & MBA
Born
1967
Holding
10 000
Independent
Yes
Assumed
Board member since 2018
Professional experience
With 25 years of experience in Life Sciences, Anders has held several Senior Executive roles in multinational pharmaceutical companies, both abroad and at home. He is currently CEO and Member of the Board of Longboat Amniotics AB, a private Biotech company operating in stem cell production & development. Anders is also a Board Member in Respiratorius AB (publ.), and Chairman of the Board in CanImGuide Theraputics AB (priv.). In addition, he serves as Industrial Advisor in Life Sciences to the Private Equity company Ratos AB (publ.).

Per Ollermark
Board member
Education
BSC
Born
1960
Holding
No
Independent
Yes
Assumed
Board member since 2021
Professional experience
More than 25 years of experience from leading finance positions in international groups, both abroad and in Sweden, the majority of which are companies within Life Science. For 10 years, interim consultant and financial advisor via his own company Turn the Key AB, with a focus on efficiency projects, turn-around, IPO preparations and traditional interim roles.

Per Svangren
Board member
Education
Pharmacist, Uppsala University
Born
1973
Holding
10 480
Independant
Yes
Assumed
Board member since 2021
Professional experience
Currently senior consultant and CEO of own consulting company Svangren Life Science Consulting AB. Has >20 years of experience in the Pharma and Med Tech industry in both local and global positions. Previous employers include Pfizer, AstraZeneca, LEO Pharma and SOBI. Ended assignment in Barsebäck Golf Country Club in March 2021 after 7 years on its board.

Rajiv I. Modi
Board member
Education
MSc Biochemical Engineering from University College, London, PhD Biological Science from the University of Michigan, Ann Arbor, USA.
Born
1960
Holding
8 718 500 via company
Independant
No
Assumed
Board member since 2015
Professional experience
Chairman and Managing Director of Cadila Pharmaceuticals.
Cadila Pharmaceuticals places immense focus on research. Being a Biotechnologist himself, Dr Modi has played a major role in developing the Company’s Biotechnology Division into a strong R&D unit, focusing on new developments and breakthrough innovations. Envisioning a global presence for the Group, Dr Modi played a pivotal role in establishing the marketing set-up and subsidiaries of the Company across the shores.
Chairman of the CII National Committee on Pharma 2015-2016. Chairman of Board of Governance of Indian Institute of Technology, Guwahati, India. Former Chairman of CII Gujarat State Council.

Linda Neckmar
Board member
Education
M.Sc. (Chemical Engineering) Lund University of Technology
Born
1973
Holding
2 500
Independant
Yes
Assumed
Board member since 2020
Professional experience
Head of Commercial Development på Chr Hansen AS. Styrelseledamot i Veg of Lund AB. Tidigare VP EMEA and APAC på Probi AB och styrelseledamot i Phase Holographic Imaging AB.